| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD79B | Synonyms | AGM6, B29, IGB, Igbeta | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q23.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | CD79b molecule | ||||
| GTO ID | GTC3578 |
| Trial ID | NCT06026319 |
| Disease | Non-Hodgkin's Lymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma | Mantle Cell Lymphoma |
| Altered gene | CD79B|CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD79b-19 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma |
| Year | 2023 |
| Country | United States |
| Company sponsor | Marcela V. Maus, M.D.,Ph.D. |
| Other ID(s) | 23-474 |
| Cohort 1 | |||||||||
|
|||||||||